BioInvent International (BINV) Investing in Life Science 2026 summary

Key scientific insights

• Immunomodulatory antibodies have transformed cancer survival, especially for tumors infiltrated by CD8-positive T cells.

• Many cancers remain unresponsive to current immunotherapies due to lack of CD8-positive T cell infiltration, but combining therapies can improve outcomes.

• Bringing CD8-positive T cells into 'cold' tumors is critical for improving patient response rates.

Lead program and mechanism of action

• The BI-1808 antibody targets TNFR2, showing activity in cold tumors by recruiting CD8-positive T cells and deleting immunosuppressive T regulatory cells.

• The antibody activates myeloid cells to release factors that attract CD8-positive T cells and eliminates highly immunosuppressive T regulatory cells.

• This dual mechanism is distinct from PD-1 inhibitors and is complementary, potentially enhancing combination therapy efficacy.

Clinical and preclinical results

• In a patient with gastrointestinal stromal tumor, BI-1808 led to significant CD8-positive T cell infiltration and tumor shrinkage, with no detectable tumors after treatment.

• Preclinical models show that combining BI-1808 with PD-1 inhibitors cures a majority of animals with resistant tumors.

• Early clinical data in ovarian cancer show a response rate of about 25% with the combination, compared to less than 10% for PD-1 alone.

• Progression-free survival with the combination reached 10 months versus just over 2 months for PD-1 monotherapy.

• The antibody is well tolerated, with no severe adverse events reported in dose escalation studies.